01:54:43 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-29 Kvartalsrapport 2024-Q3
2024-10-15 X-dag halvårsutdelning ORNBV 0.81
2024-10-15 X-dag halvårsutdelning ORNAV 0.81
2024-08-08 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-03-21 X-dag halvårsutdelning ORNAV 0.81
2024-03-21 X-dag halvårsutdelning ORNBV 0.81
2024-03-20 Årsstämma 2024
2024-02-13 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-17 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-23 X-dag ordinarie utdelning ORNAV 1.60 EUR
2023-03-23 X-dag ordinarie utdelning ORNBV 1.60 EUR
2023-03-22 Årsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-03-24 X-dag ordinarie utdelning ORNAV 1.50 EUR
2022-03-24 X-dag ordinarie utdelning ORNBV 1.50 EUR
2022-03-23 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-19 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-26 X-dag ordinarie utdelning ORNBV 1.50 EUR
2021-03-26 X-dag ordinarie utdelning ORNAV 1.50 EUR
2021-03-25 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-07 X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-05-07 X-dag ordinarie utdelning ORNAV 1.50 EUR
2020-05-06 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-03-26 X-dag ordinarie utdelning ORNBV 1.50 EUR
2020-02-05 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-17 Kvartalsrapport 2019-Q2
2019-04-25 Kvartalsrapport 2019-Q1
2019-03-27 X-dag ordinarie utdelning ORNAV 1.50 EUR
2019-03-27 X-dag ordinarie utdelning ORNBV 1.50 EUR
2019-03-26 Årsstämma 2019
2019-02-06 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-07-18 Kvartalsrapport 2018-Q2
2018-04-24 Kvartalsrapport 2018-Q1
2018-03-21 X-dag ordinarie utdelning ORNBV 1.45 EUR
2018-03-21 X-dag ordinarie utdelning ORNAV 1.45 EUR
2018-03-20 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-19 Kvartalsrapport 2017-Q2
2017-05-18 Kapitalmarknadsdag 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-03-23 X-dag bonusutdelning ORNBV 0.2
2017-03-23 X-dag ordinarie utdelning ORNAV 1.35 EUR
2017-03-23 X-dag bonusutdelning ORNAV 0.2
2017-03-23 X-dag ordinarie utdelning ORNBV 1.35 EUR
2017-03-22 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-10-25 Kvartalsrapport 2016-Q3
2016-07-19 Kvartalsrapport 2016-Q2
2016-04-27 Kvartalsrapport 2016-Q1
2016-03-23 X-dag ordinarie utdelning ORNAV 1.30 EUR
2016-03-23 X-dag ordinarie utdelning ORNBV 1.30 EUR
2016-03-22 Årsstämma 2016
2016-02-02 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-07-28 Kvartalsrapport 2015-Q2
2015-05-26 Kapitalmarknadsdag 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-03-25 X-dag ordinarie utdelning ORNBV 1.30 EUR
2015-03-25 X-dag ordinarie utdelning ORNAV 1.30 EUR
2015-03-24 Årsstämma 2015
2015-02-04 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-07-29 Kvartalsrapport 2014-Q2
2014-04-29 Kvartalsrapport 2014-Q1
2014-03-26 X-dag ordinarie utdelning ORNBV 1.25 EUR
2014-03-26 X-dag ordinarie utdelning ORNAV 1.25 EUR
2014-03-25 Årsstämma 2014
2014-02-04 Bokslutskommuniké 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-07-30 Kvartalsrapport 2013-Q2
2013-04-23 Kvartalsrapport 2013-Q1
2013-03-20 X-dag ordinarie utdelning ORNAV 1.30 EUR
2013-03-20 X-dag ordinarie utdelning ORNBV 1.30 EUR
2013-03-19 Årsstämma 2013
2013-02-05 Bokslutskommuniké 2012
2012-10-23 Kvartalsrapport 2012-Q3
2012-07-31 Kvartalsrapport 2012-Q2
2012-05-24 Kapitalmarknadsdag 2012
2012-04-24 Kvartalsrapport 2012-Q1
2012-03-21 X-dag ordinarie utdelning ORNBV 1.30 EUR
2012-03-21 X-dag ordinarie utdelning ORNAV 1.30 EUR
2012-03-21 X-dag bonusutdelning ORNAV 0.12
2012-03-21 X-dag bonusutdelning ORNBV 0.12
2012-03-20 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-10-25 Kvartalsrapport 2011-Q3
2011-08-02 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-01 X-dag bonusutdelning ORNAV 0.06
2011-04-01 X-dag ordinarie utdelning ORNAV 1.20 EUR
2011-04-01 X-dag ordinarie utdelning ORNBV 1.20 EUR
2011-04-01 X-dag bonusutdelning ORNBV 0.06
2011-03-31 Årsstämma 2011
2011-02-09 Bokslutskommuniké 2010
2010-10-26 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-04-27 Kvartalsrapport 2010-Q1
2010-03-25 X-dag bonusutdelning ORNBV 0.1
2010-03-25 X-dag ordinarie utdelning ORNBV 1.00 EUR
2010-03-25 X-dag ordinarie utdelning ORNAV 1.00 EUR
2010-03-25 X-dag bonusutdelning ORNAV 0.1
2009-03-24 X-dag ordinarie utdelning ORNBV 0.95 EUR
2009-03-24 X-dag ordinarie utdelning ORNAV 0.95 EUR
2008-03-26 X-dag ordinarie utdelning ORNBV 1.00 EUR
2007-04-03 X-dag ordinarie utdelning ORNAV 1.00 EUR
2007-04-03 X-dag ordinarie utdelning ORNBV 1.00 EUR
2006-03-22 X-dag ordinarie utdelning ORNBV 0.85 EUR
2005-03-22 X-dag ordinarie utdelning ORNAV 0.55 EUR
2005-03-22 X-dag ordinarie utdelning ORNBV 0.55 EUR
2004-09-15 X-dag bonusutdelning ORNBV 2.14
2004-09-15 X-dag bonusutdelning ORNAV 2.14
2004-03-23 X-dag ordinarie utdelning ORNAV 1.60 EUR
2004-03-23 X-dag ordinarie utdelning ORNBV 1.60 EUR
2003-12-12 X-dag bonusutdelning ORNBV 1.5
2003-12-12 X-dag bonusutdelning ORNAV 1.5
2003-03-23 X-dag ordinarie utdelning ORNAV 0.93 EUR
2003-03-23 X-dag ordinarie utdelning ORNBV 0.93 EUR
2002-04-16 X-dag ordinarie utdelning ORNAV 1.10 EUR
2002-04-16 X-dag ordinarie utdelning ORNBV 1.10 EUR
2001-03-30 X-dag ordinarie utdelning ORNAV 1.20 EUR
2001-03-30 X-dag ordinarie utdelning ORNBV 1.20 EUR
2000-03-31 X-dag ordinarie utdelning ORNBV 1.18 EUR
2000-03-31 X-dag ordinarie utdelning ORNAV 1.18 EUR
1999-07-28 X-dag bonusutdelning ORNBV 13.46
1999-07-28 X-dag bonusutdelning ORNAV 13.46
1999-04-09 X-dag ordinarie utdelning ORNAV 6.50 EUR
1999-04-09 X-dag ordinarie utdelning ORNBV 6.50 EUR
1998-04-21 X-dag ordinarie utdelning ORNBV 7.50 EUR
1998-04-21 X-dag ordinarie utdelning ORNAV 7.50 EUR
1997-04-22 X-dag ordinarie utdelning ORNBV 5.00 EUR
1997-04-22 X-dag ordinarie utdelning ORNAV 5.00 EUR
1996-04-23 X-dag ordinarie utdelning ORNAV 4.00 EUR
1996-04-23 X-dag ordinarie utdelning ORNBV 4.00 EUR

Beskrivning

LandFinland
ListaLarge Cap Helsinki
SektorHälsovård
IndustriLäkemedel & Handel
Orion är en koncern med verksamhet inom läkemedelsindustrin. Bolaget bedriver forskning och utveckling av humana- och veterinära läkemedel, där störst fokus innehas inom sjukdomar som drabbar nervsystemet, samt onkologi och luftvägssjukdomar. Idag återfinns bolagets produkter på global nivå, med störst närvaro inom Norden och övriga Europa. Bolagets huvudkontor ligger i Esbo, Finland.
2022-02-18 07:30:00

                                                                     

ORION CORPORATION    PRESS RELEASE   18 FEBRUARY 2022 AT 8.30 A.M. EET     

Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU


Clinical phase I data on Orion Corporation’s ODM-208, a first-in-class oral, non-steroidal and selective inhibitor of CYP11A1, the first and rate-limiting enzyme of steroid biosynthesis, were presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). CYPIDES phase 1 data shows that ODM-208 effectively blocked the production of all steroid hormones in men with metastatic castration-resistant prostate cancer (mCRPC) and showed promising anti-tumor activity in men progressing despite extensive prior treatment with both novel hormonal therapies (NHT’s) and taxanes. Treatment responses to ODM-208 especially occurred in men with activating androgen receptor (AR) mutations.

ODM-208 is a complete blocker of steroid biosynthesis that suppresses the production of all steroid hormones and their precursors that may activate the androgen receptor (AR) signalling pathway. This is particularly relevant in patients with AR ligand binding domain (LBD) activating somatic point mutations, a mechanism of resistance to hormone-based therapies in metastatic castration-resistant prostate cancer (mCRPC). During treatment the patients receive hormone replacement therapy to ensure sufficient adrenal function.

In CYPIDES phase I, a total of 44 patients with median age of 70 years received ODM-208. Overall, 32% of the patients achieved a PSA (prostate specific antigen) decrease of ≥50%. Of patients with AR LBD mutation (17), 68% achieved a PSA decrease of ≥50%. Also, prolonged treatment responses were observed especially in patients with AR LBD mutation. Although tolerated by most patients, the main safety finding was adrenal insufficiency (AI). Overall, 14 (32%) patients experienced severe adrenal insufficiency despite the replacement therapy requiring further adrenal supplementation after which the ODM-208 treatment commonly continued. Non-adrenal adverse events were unremarkable.

Taru Blom (MD, PhD), Vice President, Global Development and CMO, Orion R&D comments:

“ODM-208 is a first-in-class CYP11A1-inhibitor and we are excited that this novel approach works in some of the patients who have only a few effective treatment options available. The first results of CYPIDES are encouraging, and more studies are needed to confirm the potential of ODM-208 as a treatment option for men with advanced prostate cancer. In addition, we are focusing on the safety findings of the study as well as are looking into the optimization of the adrenal balance of the patients through appropriate replacement therapy.”

More information about the CYPIDES trial: www.clinicaltrials.gov, Identifier: NCT03436485

The Phase II dose expansion part of CYPIDES is ongoing.

Phase I/II clinical trial CYPIDES

The Phase I/II trial CYPIDES investigates the safety, pharmacokinetics and anti-tumor activity of ODM-208 in men with mCRPC. The Phase I started in 2018 and has recruited 44 patients. More information about the trial: www.clinicaltrials.gov, Identifier: NCT03436485

ODM-208 investigational drug

ODM-208 is a novel, oral, non-steroidal and selective inhibitor of CYP11A1 enzyme developed by Orion for the treatment of prostate cancer. CYP11A1 is the rate-limiting enzyme of the steroid biosynthesis. By inhibiting CYP11A1 enzyme activity, ODM-208 suppresses the production of all steroid hormones and their precursors that may activate AR signalling pathway. Orion is the first pharmaceutical company to develop a selective drug that works by this mechanism.

Contact persons:

Taru Blom
Vice President, Global Development and CMO, Orion R&D, Orion Corporation
taru.blom@orionpharma.com
Tel. +358 50 966 7836

Contact person for the media:
Terhi Ormio
Vice President, Communicatios, Orion Corporation
terhi.ormio@orion.fi
Tel. +358 50 966 4646

Publisher:
Orion Corporation
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.